eFFECTOR Therapeutics Stock

effector.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $152.08MM

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to eFFECTOR Therapeutics before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

eFFECTOR Therapeutics Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

eFFECTOR Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/24/2017 Series C $39.1MM $xx.xx $197.73MM Abbvie Biotech Ventures, Abingworth, Alexandria Venture Investments, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Novartis Venture Fund, Pfizer Venture Investments, Sectoral Asset Management, Sr One, The Column Group, U.S. Venture Partners
Price per Share
$xx.xx
Shares Outstanding
76,070,076
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abbvie Biotech Ventures, Abingworth, Alexandria Venture Investments, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Novartis Venture Fund, Pfizer Venture Investments, Sectoral Asset Management, Sr One, The Column Group, U.S. Venture Partners
12/22/2015 Series B $56MM $xx.xx $141.22MM Abbvie Biotech Ventures, Abingworth, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Mission Bay Capital, Novartis Venture Fund, Osage University Partners, Sr One, The Column Group, Us Venture Partners
Price per Share
$xx.xx
Shares Outstanding
114,646,041
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abbvie Biotech Ventures, Abingworth, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Mission Bay Capital, Novartis Venture Fund, Osage University Partners, Sr One, The Column Group, Us Venture Partners
05/20/2013 Series A $56.98MM $xx.xx $67.04MM Abingworth, Astellas Venture Management, Mission Bay Capital, Novartis Venture Funds, Osage University Partners, Sr One, U.S. Venture Partners
Price per Share
$xx.xx
Shares Outstanding
145,560,097
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
11.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abingworth, Astellas Venture Management, Mission Bay Capital, Novartis Venture Funds, Osage University Partners, Sr One, U.S. Venture Partners

Leadership & Board

Leadership

Stephen Worland Ph.D
Chief Executive Officer, President, Board Member & Co-Founder
Davide Ruggero Ph.D
Co-Founder
Kevin Webster Ph.D
Senior Vice President of Cancer Biology
Alana McNulty
Chief Financial Officer
Debra Vallner Ph.D
Vice President of Development Operations
Kevan Shokat Ph.D
Co-Founder and Member of Scientific Advisory Board
Siegfried Reich Ph.D
Senior Vice President, Research & Co-Founder
Annette Matthies Ph.D
Vice President of Corporate Development
Jeremy Barton MD
Chief Medical Officer

Board

David Maki JD
Altitude Life Science Ventures
Ken Haas JD
Markus Goebel Ph.D
Novartis Venture Fund
Elaine Jones Ph.D
Pfizer Ventures
Laurence Lasky Ph.D
US Venture Partners
Stephen Worland Ph.D
Jonathan Root MD
US Venture Partners
KT Moortgat Ph.D
AbbVie Ventures
Simeon George MD
SR One

eFFECTOR Therapeutics stock FAQs

plusminus

Can you buy eFFECTOR Therapeutics stock?

You can no longer buy eFFECTOR Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy eFFECTOR Therapeutics stock?

You can no longer buy eFFECTOR Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell eFFECTOR Therapeutics stock?

You can no longer sell stock of eFFECTOR Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell eFFECTOR Therapeutics stock?

You can no longer sell stock of eFFECTOR Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is eFFECTOR Therapeutics a public company?

eFFECTOR Therapeutics is now a public company traded on NASDAQ with ticker EFTR.
plusminus

What is eFFECTOR Therapeutics’ stock price?

The stock price of eFFECTOR Therapeutics is $10.6 as of 1/18/24.
plusminus

What is eFFECTOR Therapeutics’ stock ticker symbol?

The ticker symbol of eFFECTOR Therapeutics is EFTR.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

eFFECTOR Therapeutics News and Media Highlights

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose acquisition company, announced today that the Company’s stockholders have approved all proposals related to the previously announced business combination (the “Business Combination”) with eFFECTOR Therapeutics, Inc. (“eFFECTOR”) at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC’s outstanding shares, voted to approve the Business Combination.

Xconomy: Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs

San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing,

eFFECTOR Therapeutics Increases its Series B Financing Round to $56M

/PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today...

Effector Therapeutics Boosts Series B to $56M

Cancer drug developers often take aim at disease-triggering proteins, but with $56 million in Series B financing, Effector Therapeutics Inc. aims to show that there is another way to develop molecularly targeted oncology products.
Browse Insights
Updated on: Dec 4, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.